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INTRODUCTION 
Lung cancer accounts for the highest cancer-related mortality rate worldwide.1 Accurate 
mediastinal nodal staging is crucial in the management of non-small cell lung cancer (NSCLC) 
as it directs therapy and has prognostic value.2,3  
ASTER (Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer: a 
Randomized Clinical Trial) compared a surgical  (mediastinoscopy) with an endosonographic 
staging strategy (combined use of endobronchial and transesophageal ultrasound, followed by 
mediastinoscopy if negative).4 The endosonographic strategy was significantly more sensitive for 
diagnosing mediastinal nodal metastases than surgical staging (94% vs 79%).  
If mediastinal staging is improved, more patients should receive optimal treatment and might 
survive longer. The current post-hoc analysis evaluated survival in ASTER.  
 
METHODS 
Of 241 patients with potentially resectable NSCLC, 123 were randomized to the 
endosonographic and 118 to the surgical staging strategy in 4 tertiary referral centers in Leiden 
(the Netherlands), Ghent and Leuven (Belgium) and Cambridge (United Kingdom) between 
February 2007 and April 2009.4 Surgical-pathological staging was the reference standard for 
mediastinal nodal assessment. The current analysis was either approved or waived by the 
involved ethical committees.  
Between 30 June and 15 October 2015, survival data were obtained through patient records, 
death registers or contact with general practitioners.  
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The proportion of survivors at 5 years for both staging strategies and odds ratios with 95% 
confidence intervals were calculated. Kaplan-Meier analysis was performed to compare median 
survival across the strategies. Patients with no date of death were censored on the date they were 
last known to be alive. Subgroup analysis was performed for patients with nodal stages N2/N3 
and N0/N1. Data were analyzed using SPSS v.22. (SPSS Inc, Chicago, Illinois). 
 
RESULTS 
Survival data were obtained for 237/241 patients (98%) - 182 males (77%) - with a mean age at 
randomization of 65 years (SD 9). 
Survival at 5 years was 35% (42/121) for the endosonographic versus 35% (41/116) for the 
surgical strategy (odds ratio 0.97 (95% CI 0.57-1.66)) (Table). The estimated median survival 
was 31 months (95% CI 21-41) versus 33 months (95% CI 23-43), respectively (hazard ratio 
1.04 (95% CI 0.77-1.40) (Figure).  
In the subgroup of patients with N2/N3 metastases, survival was 17% (11/64) in the 
endosonographic versus 19% (10/52) in the surgical group (odds ratio 0.87 (95%CI 0.34-2.25)). 
In the subgroup of patients with N0/N1 metastases, survival was 54% (31/57) versus 48% 
(31/64), respectively (odds ratio 1.27 (95% CI 0.62-2.60)). 
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DISCUSSION 
No survival difference was found 5 years following randomization to an endosonographic or 
surgical staging strategy of patients with NSCLC. Since the original results of ASTER were 
published, clinical guidelines on lung cancer management underwent major revisions and now 
advocate endosonography instead of mediastinoscopy- as the initial step for mediastinal nodal 
staging.2,3 The endosonographic strategy is more accurate, less invasive, reduces unnecessary 
thoracotomies 4 and is cost-effective.5 
Data from a recent randomized trial shows prolonged survival in patients who underwent 
endosonography compared to conventional staging.6 However, most patients in the latter group 
underwent bronchoscopy instead of mediastinoscopy. To our knowledge, ASTER is the first 
randomized trial to evaluate survival outcomes between endosonographic and surgical staging 
strategies.  
Why did improved mediastinal staging not lead to improved survival? Missing data occurred in 
less than 2% and therefore are an unlikely source of bias. However, by chance, the prevalence of 
mediastinal nodal metastases in the surgical group was lower compared to the endosonography 
group (44% versus 54%). This might have negatively affected survival in the latter group. Also, 
ASTER was powered to detect a difference in diagnostic sensitivity, not survival. This is the 
main limitation of the current analysis and reflected by the wide confidence intervals. If a 
survival difference between the strategies exists, it is likely to be small and a larger sample size 
may be needed to detect it. However, randomized trials to detect a survival difference upon 
staging strategy are not likely to be conducted as the endosonographic strategy is now advised in 
clinical guidelines.2,3  
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TABLE 
 
Table: Survival of the endosonographic versus the surgical staging strategy. 
 Survival at 5 years 
n/N (%) 
Odds ratio 
(95% CI) 
Estimated median survival  
in months (95%CI) 
Hazard ratio 
(95%CI) 
Overall 83/237 (35)  33 (26-40)  
Endosonographic staging strategy 42/121 (35) 0.97 (0.57-1.66) 31 (21-41) 1.04 (0.77-1.40) 
Surgical staging strategy 41/116 (35)  33 (23-43)  
     
N2/N3 21/116 (18)  21 (17-25)  
Endosonographic staging strategy 11/64 (17) 0.87 (0.34-2.25) 21 (15-27) 1.04 (0.70-1.55) 
Surgical staging strategy 10/52 (19)  22 (15-27)  
     
N0/N1 62/121 (51)  62 (39-85)  
Endosonographic staging strategy 31/57 (54) 1.27 (0.62-2.60) 72 (38-106) 0.91 (0.57-1.44) 
Surgical staging strategy 31/64 (48)  57 (30-84)  
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FIGURE 
 
Figure: Survival in the endosonographic versus the surgical staging strategy. 
 
